AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04351815 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No specific intervention
Description: * Standard care: Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patients will be asked to maintain regular physical activity without support~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)
Study NCT04298853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine PRN
Description: Dose given every 3 hours as-needed for severe NAS, defined by a threshold Finnegan score.
Study NCT04298853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine scheduled
Description: Dose given every 3 hours on a scheduled basis and slowly weaned once stabilized.
Study NCT04201353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer
Description: The intervention is a monthly cash transfer of 22,500 Tanzanian Shillings (\~$10) for up to 6 months conditional on visit attendance.
Study NCT03037671 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitor (CGM)
Description: Participants will wear the continuous glucose monitor (GCM) device during the peri-HSCT period for the duration of their initial hospital admission. No intervention based on results.
Study NCT00834795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg tablets
Description: 1 x 25 mg
Study NCT00834795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COREG® 25 mg tablets
Description: 1 x 25 mg
Study NCT02189096 — intervention group
Intervention type: OTHER
Intervention: NEWS and Sepsis Screening
Description: Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
Study NCT02189096 — intervention group
Intervention type: OTHER
Intervention: Point of care lactate measurement
Description: Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
Study NCT05363059 — intervention group
Intervention type: DRUG
Intervention: Hypoglycemic drugs
Description: drug
Study NCT05363059 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: surgery
Study NCT04137575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ConquerFear-Group
Description: The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy. The intervention will be delivered on Zoom, a secure online platform.
Study NCT04137575 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Relaxation Training
Description: The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training. The intervention will be delivered on Zoom, a secure online platform.
Study NCT01798719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Mediterranean Diet
Description: A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
Study NCT01798719 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Advice
Description: Only general advice about diet
Study NCT02877433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Roxolid short implant, 4 mm length (4)
Description: Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
Study NCT02877433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roxolid short implant, 4 mm length (2)
Description: Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
Study NCT01718704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viberect device
Description: Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
Study NCT05365932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra auricular device (IAD)
Description: The Intra Auricular Device (IADs) are a pair of inconspicuous, custom fit auricular prosthetic devices.The ear inserts are manufactured using computer-aided design/computer-aided manufacturing (CAD/CAM) technology and are made from a liquid, photo-reactive acrylate (EShell 300), used in hearing aid shells and otoplastics for the last 10 years. They are designed to be placed into the outer third of the ear canals, and they have a small retraction post used to facilitate removal . A red or blue dot, respectively, indicates the right and the left side. The device do not interfere with hearing or speech
Study NCT01929863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be supplied as oral solution, and will be administered BID \[45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period\]
Study NCT01929863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
Study NCT01929863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
Study NCT04890418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketalar, 5 mg/mL Injectable Solution
Description: The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.
Study NCT04890418 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive 10 mL of 0.9% saline. This injection is also performed after the realization of PNB but before tourniquet set up and before start of surgery.
Study NCT00568672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 5 mg / day for 6 months
Study NCT00568672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 5 mg / day for 6 months
Study NCT03810703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule
Study NCT03810703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg oral capsule
Description: d-amphetamine 10 mg oral capsule
Study NCT03810703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg oral capsule
Description: d-amphetamine 20 mg oral capsule
Study NCT01202734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl
Description: Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
Study NCT02849457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Early Vigabatrin
Description: Subjects randomized to vigabatrin will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
Study NCT02849457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Vigabatrin
Description: Subjects randomized to vigabatrin will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
Study NCT02849457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Vigabatrin (Placebo)
Description: Subjects randomized to placebo will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
Study NCT03818581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: 10-mg or 20-mg Suvorexant capsules
Study NCT00430365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: oral drug
Study NCT00430365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo
Study NCT02919332 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo 18F-FDG PET/CT
Study NCT02919332 — intervention group
Intervention type: RADIATION
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT02919332 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo 18F-FDG PET/CT
Study NCT01060956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reporting of two different bacteria in urine culture
Description: reporting of two different bacteria in urine culture
Study NCT01060956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: reporting mixed growth on urine culture
Description: reporting mixed growth on urine culture
Study NCT03930433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
Study NCT03930433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diltiazem
Description: Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
Study NCT03930433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebivolol+Diltiazem
Description: Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
Study NCT04569370 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Surgical removal of Gall bladder using laparoscopy
Study NCT03969420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib (flavopiridol) and cytarabine (Ara-C)
Description: Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection
Study NCT03969420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib (flavopiridol)
Description: Administered intravenously
Study NCT03996213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: head down position
Description: Head-down position will be achieved by 30 degrees tilting of the whole operating table 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
Study NCT03996213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: leg elevation position
Description: Leg elevation position will be achieved by raising the patient legs for 30 cm using two standard pillows positioned under the heels 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
Study NCT00335075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
Study NCT00335075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semustine
Description: Semustine orally once every 28 days at a dose of 150 mg/m2/day.
Study NCT00331487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
Study NCT00331487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
Study NCT01741818 — intervention group
Intervention type: OTHER
Intervention: Measuring IVC collapsibility index by bedside ultrasonography
Study NCT02596672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The friendly walking group
Description: A 12 week peer led walking group for adults and older adults (> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
Study NCT02547935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Tablets administered orally once daily for 24 weeks.
Study NCT02547935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg
Description: Tablets administered orally once daily for 24 weeks.
Study NCT02547935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Description: Tablets administered orally once daily for 24 weeks.
Study NCT03735342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio Recording
Description: All participants will be provided with a re-playable audio recording of the discharge discussion on a portable electronic device. In addition, participants will have the option to record the discharge discussion on a personally-owned smartphone or receive access to the recording online, via the Open Recording Automated Logging System (ORALS).
Study NCT02858258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP/R-DHAP
Description: Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
Study NCT02858258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP/R-DHAP
Description: Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
Study NCT02858258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Induction)
Description: Ibrutinib: only in cycle 1,3,5 on Day 1-19
Study NCT02858258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCT conditioning
Description: ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)
Study NCT02858258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASCT conditioning
Description: ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)
Study NCT02858258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Maintenance)
Description: Ibrutinib (Maintenance), daily 560 mg for 2 years;
Study NCT02951299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400Mg Tablet
Description: Investigators with AKI will received oral pentoxifylline (400 mg) three times a day for 14 days or no pentoxifylline according to their decision.
Study NCT01767285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel implant
Description: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
Study NCT01767285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant
Description: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
Study NCT01095770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF Ablation with Ablation Frontiers Technology
Description: AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.
Study NCT01095770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF Ablation with LASSO catheter
Description: AF Ablation with traditional LASSO catheter
Study NCT01095770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reveal XT
Description: Reveal XT implantable loop recorder monitored group
Study NCT01095770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent Dual Chamber Pacemaker
Description: This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.
Study NCT03948425 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: spectral CT
Description: Head spectral CT
Study NCT01727154 — intervention group
Intervention type: BIOLOGICAL
Intervention: Sipuleucel-T
Description: Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
Study NCT03237663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The oral O1 / O139 cholera vaccine (enteric capsules)
Study NCT04705753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cretan IAMA
Description: Cretan IAMA (CAPeo) soft gels, 1 ml/day of a 1.5% essential oil combination from three aromatic plants (Thymbra 59 capitata (L.) Cav., Origanum dictamnus L., Salvia fruticosa Mill.) in extra virgin olive oil
Study NCT03622840 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Remediation
Description: Weekly 30-45mins Cognitive Remediation Sessions over 11 weeks
Study NCT00441896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Study NCT00441896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01101048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
Study NCT01101048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 167
Description: Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
Study NCT02927483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Endolex Forte®
Description: Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
Study NCT02927483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A combination of diosmin and hesperidin
Description: A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
Study NCT03274297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.